- Brand names:
- Pharmaceutical Company:
- Condition/Indication: Advanced and metastatic cancers
- Meeting Date: December 2025
- Public Summary Document (PSD) December 2025 PBAC Meeting - (PDF 1.3MB)
- Public Summary Document (PSD) December 2025 PBAC Meeting - (Word 277.9KB)
Pembrolizumab – December 2025
Pembrolizumab: Powder and suspension for injection (0.5 mL); Keytruda® - December 2025
Last updated
10 December 2025